NCT05269940View on ClinicalTrials.gov

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

January 24, 2023

Study Completion Date

July 5, 2024

Conditions
Non Hodgkin LymphomaPeripheral T Cell LymphomaCLL/SLL
Interventions
DRUG

ZX-101A

oral dosing, once daily

Trial Locations (3)

Unknown

Anhui Medical University No.4 Affiliated Hospital, Hefei

Wuhan Union Hospital, Wuhan

Hunan Tumor Hospital, Changsha

Sponsors
All Listed Sponsors
lead

Nanjing Zenshine Pharmaceuticals

INDUSTRY

NCT05269940 - A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies | Biotech Hunter | Biotech Hunter